SAN CARLOS, Calif., November 7, 2022 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) BCELa clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced today that it will be presenting at the following upcoming conferences:
Kuhn 6th Annual IO Next Summit
November 11, 2022
Fireside Chat: 2:40-3:00 a.m. EST, November 11, 2022
Stifel Health Conference
15-16 November 2022
Fireside Chat: 8:00 a.m. – 8:30 a.m. EST, November 15, 2022
Evercore ISI HealthCONx Conference
November 29 – December 1, 2022
Fireside Chat: 9:40-10:00 a.m. EST, December 1, 2022
Live webcasts of the presentations can be accessed through the Events & Presentations section of the company’s website at http://ir.atreca.com. An archived replay of each presentation will be available on the company’s website for 30 days after the live broadcast.
About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated from its differentiated research platform. Atreca’s platform provides access to an uncharted landscape in oncology by identifying unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies form the basis of first-in-class therapeutic candidates such as our lead product candidates ATRC-101, a monoclonal antibody targeting a novel ribonucleoprotein complex, and ATRC-301, an antibody-drug conjugate targeting a novel epitope on EphA2. A Phase 1b study evaluating ATRC-101 in multiple solid cancers is enrolling patients and ATRC-301 is in IND-enabling studies. For more information about Atreca, see www.atreca.com.
Forward-Looking Statements
This press release contains statements of matter that are not historical facts, but are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995….
[ad_2]
Source story
